Spring blooms with fresh PBS listing

A first-of-its-kind targeted treatment for Australians with kidney disease caused by lupus will be reimbursed from next month.

Roche's Gazyva has won a PBS listing from 1 September for about 3,500 Australians with severe kidney disease caused by lupus, known as lupus nephritis. It will be taken in addition to existing treatment.

“The addition of this new therapy to the PBS is a significant development in how we treat lupus-related kidney disease in Australia,” Monash University and Monash Health Director of Rheumatology, Professor Eric Morand said.

To see the whole article please log in.

Christine Spiteri

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here